Matthew Faber

Company: Xencor

Job title: Senior Scientist

Seminars:

XmAb541: A Selectivity Engineered XmAb 2+1 CLDN6 x CD3 Bispecific Antibody for Treatment of Ovarian Cancer & Other CLDN6+ Solid Tumors 1:30 pm

Xencor’s XmAb® platforms allow for the rapid development of therapeutic bispecific with novel formats/binding modes that engage T cells (xCD3, xCD28) or NK cells xNKp46, xNKG2D) or act though other mechanisms in oncology, autoimmune, and inflammatory disorders. Analysis of genomic/transcriptomic data to identify CLDN6 as an antigen with high expression in ovarian cancer tumors with…Read more

day: Day One